{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T14:26:00Z","timestamp":1774448760341,"version":"3.50.1"},"reference-count":34,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2009,9]]},"DOI":"10.1097\/bor.0b013e32832f1445","type":"journal-article","created":{"date-parts":[[2009,8,13]],"date-time":"2009-08-13T18:53:58Z","timestamp":1250189638000},"page":"533-537","source":"Crossref","is-referenced-by-count":29,"title":["Targeting interleukin-6 in pediatric rheumatic diseases"],"prefix":"10.1097","volume":"21","author":[{"given":"Fabrizio","family":"De Benedetti","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-17-20210128","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1146\/annurev.immunol.23.021704.115806","article-title":"Interleukin-6: from basic science to medicine: 40 years in immunology","volume":"23","author":"Kishimoto","year":"2005","journal-title":"Annu Rev Immunol"},{"key":"R2-17-20210128","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1038\/nature04753","article-title":"Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells","volume":"441","author":"Bettelli","year":"2006","journal-title":"Nature"},{"key":"R3-17-20210128","doi-asserted-by":"crossref","first-page":"3710","DOI":"10.1002\/art.24126","article-title":"Interleukin-6 blockade suppresses autoimmune arthritis in mice by the inhibition of inflammatory Th17 responses","volume":"58","author":"Fujimoto","year":"2008","journal-title":"Arthritis Rheum"},{"key":"R4-17-20210128","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1038\/nrrheum.2009.80","article-title":"Type 17 T helper cells-origins, features and possible roles in rheumatic disease","volume":"5","author":"Annunziato","year":"2009","journal-title":"Nat Rev Rheumatol"},{"key":"R5-17-20210128","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1002\/art.24498","article-title":"Transmembrane BAFF from rheumatoid synoviocytes requires interleukin-6 to induce the expression of recombination-activating gene in B lymphocytes","volume":"60","author":"Rochas","year":"2009","journal-title":"Arthritis Rheum"},{"key":"R6-17-20210128","doi-asserted-by":"crossref","first-page":"3840","DOI":"10.1016\/j.molimm.2008.05.011","article-title":"The kappa immunoglobulin light chain repertoire of peripheral blood B cells in patients with juvenile rheumatoid arthritis","volume":"45","author":"Morbach","year":"2008","journal-title":"Mol Immunol"},{"key":"R7-17-20210128","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1016\/S1074-7613(01)00151-0","article-title":"Il-6 and its soluble receptor orchestrate a temporal switch in the pattern of leukocyte recruitment seen during acute inflammation","volume":"14","author":"Hurst","year":"2001","journal-title":"Immunity"},{"key":"R8-17-20210128","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1002\/art.11143","article-title":"Antiinterleukin-6 receptor antibody therapy reduces vascular endothelial growth factor production in rheumatoid arthritis","volume":"48","author":"Nakahara","year":"2003","journal-title":"Arthritis Rheum"},{"key":"R9-17-20210128","doi-asserted-by":"crossref","first-page":"12","DOI":"10.3109\/s10165-008-0125-1","article-title":"Study of active controlled tocilizumab monotherapy for rheumatoid arthritis patients with an inadequate response to methotrexate (SATORI): significant reduction in disease activity and serum vascular endothelial growth factor by IL-6 receptor inhibition therapy","volume":"19","author":"Nishimoto","year":"2009","journal-title":"Mod Rheumatol"},{"key":"R10-17-20210128","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1002\/art.21537","article-title":"Interleukin-6 modulates production of T lymphocyte-derived cytokines in antigen-induced arthritis and drives inflammation-induced osteoclastogenesis","volume":"54","author":"Wong","year":"2006","journal-title":"Arthritis Rheum"},{"key":"R11-17-20210128","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1016\/j.yexmp.2008.03.003","article-title":"Early effects of tocilizumab on bone and bone marrow lesions in a collagen-induced arthritis monkey model","volume":"84","author":"Kato","year":"2008","journal-title":"Exp Mol Pathol"},{"key":"R12-17-20210128","doi-asserted-by":"crossref","first-page":"1516","DOI":"10.1136\/ard.2008.092932","article-title":"IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to antitumour necrosis factor biologicals: results from a 24-week multicentre randomised placebo-controlled trial","volume":"67","author":"Emery","year":"2008","journal-title":"Ann Rheum Dis"},{"key":"R13-17-20210128","doi-asserted-by":"crossref","first-page":"2968","DOI":"10.1002\/art.23940","article-title":"Interleukin-6 receptor inhibition with tocilizumab reduces disease activity in rheumatoid arthritis with inadequate response to disease-modifying antirheumatic drugs: the tocilizumab in combination with traditional disease-modifying antirheumatic drug therapy study","volume":"58","author":"Genovese","year":"2008","journal-title":"Arthritis Rheum"},{"key":"R15-17-20210128","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1016\/S0140-6736(08)60453-5","article-title":"Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial","volume":"371","author":"Smolen","year":"2008","journal-title":"Lancet"},{"key":"R16-17-20210128","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1016\/j.semarthrit.2008.01.006","article-title":"Role of interleukin-6 in the anemia of chronic disease","volume":"38","author":"Raj","year":"2009","journal-title":"Semin Arthritis Rheum"},{"key":"R17-17-20210128","doi-asserted-by":"crossref","first-page":"857","DOI":"10.3324\/haematol.10794","article-title":"Antiinterleukin 6 receptor antibody tocilizumab reduces the level of serum hepcidin in patients with multicentric Castleman's disease","volume":"92","author":"Kawabata","year":"2007","journal-title":"Haematologica"},{"key":"R18-17-20210128","doi-asserted-by":"crossref","first-page":"3551","DOI":"10.1002\/art.22175","article-title":"Impaired skeletal development in interleukin-6-transgenic mice: a model for the impact of chronic inflammation on the growing skeletal system","volume":"54","author":"De Benedetti","year":"2006","journal-title":"Arthritis Rheum"},{"key":"R19-17-20210128","first-page":"534","article-title":"The anti-IL-6 receptor inhibitor tocilizumab combined with MTX induces a rapid and sustained decrease of bone and cartilage degradation in patients with rheumatoid arthritis [abstract]","volume":"58","author":"Garnero","year":"2008","journal-title":"Arthritis Rheum"},{"key":"R20-17-20210128","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1172\/JCI119207","article-title":"Interleukin 6 causes growth impairment in transgenic mice through a decrease in insulin-like growth factor-I: a model for stunted growth in children with chronic inflammation","volume":"99","author":"De Benedetti","year":"1997","journal-title":"J Clin Invest"},{"key":"R21-17-20210128","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1038\/nbt0908-957","article-title":"Actemra poised to launch IL-6 inhibitors","volume":"26","author":"Melton","year":"2008","journal-title":"Nat Biotechnol"},{"key":"R22-17-20210128","doi-asserted-by":"crossref","first-page":"3959","DOI":"10.1182\/blood-2008-05-155846","article-title":"Mechanisms and pathologic significances in increase in serum interleukin-6 (IL-6) and soluble IL-6 receptor after administration of an anti-IL-6 receptor antibody, tocilizumab, in patients with rheumatoid arthritis and Castleman disease","volume":"112","author":"Nishimoto","year":"2008","journal-title":"Blood"},{"key":"R23-17-20210128","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.1016\/j.intimp.2008.07.002","article-title":"Anti-IL-6 receptor antibody increases blood IL-6 level via the blockade of IL-6 clearance, but not via the induction of IL-6 production","volume":"8","author":"Uchiyama","year":"2008","journal-title":"Int Immunopharmacol"},{"key":"R24-17-20210128","doi-asserted-by":"crossref","first-page":"e78","DOI":"10.1371\/journal.pmed.0050078","article-title":"Long-term interleukin-6 levels and subsequent risk of coronary heart disease: two new prospective studies and a systematic review","volume":"5","author":"Danesh","year":"2008","journal-title":"PLoS Med"},{"key":"R25-17-20210128","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1002\/art.20946","article-title":"Targeting the interleukin-6 receptor: a new treatment for systemic juvenile idiopathic arthritis?","volume":"52","author":"de Benedetti","year":"2005","journal-title":"Arthritis Rheum"},{"key":"R26-17-20210128","doi-asserted-by":"crossref","first-page":"R1281","DOI":"10.1186\/ar1826","article-title":"Open label phase II trial of single, ascending doses of MRA in Caucasian children with severe systemic juvenile idiopathic arthritis: proof of principle of the efficacy of IL-6 receptor blockade in this type of arthritis and demonstration of prolonged clinical improvement","volume":"7","author":"Woo","year":"2005","journal-title":"Arthritis Res Ther"},{"key":"R27-17-20210128","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1002\/art.20944","article-title":"Therapeutic efficacy of humanized recombinant antiinterleukin-6 receptor antibody in children with systemic-onset juvenile idiopathic arthritis","volume":"52","author":"Yokota","year":"2005","journal-title":"Arthritis Rheum"},{"key":"R28-17-20210128","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1016\/S0140-6736(08)60454-7","article-title":"Efficacy and safety of tocilizumab in patients with systemic-onset juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled, withdrawal phase III trial","volume":"371","author":"Yokota","year":"2008","journal-title":"Lancet"},{"key":"R29-17-20210128","doi-asserted-by":"crossref","first-page":"42","DOI":"10.3109\/s10165-008-0115-3","article-title":"Improvement of reduced serum cartilage oligomeric matrix protein levels in systemic juvenile idiopathic arthritis patients treated with the antiinterleukin-6 receptor monoclonal antibody tocilizumab","volume":"19","author":"Nakajima","year":"2009","journal-title":"Mod Rheumatol"},{"key":"R30-17-20210128","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1002\/art.23437","article-title":"The pattern of response to antiinterleukin-1 treatment distinguishes two subsets of patients with systemic-onset juvenile idiopathic arthritis","volume":"58","author":"Gattorno","year":"2008","journal-title":"Arthritis Rheum"},{"key":"R31-17-20210128","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1136\/ard.2007.076034","article-title":"Interleukin-1 receptor antagonist (anakinra) treatment in patients with systemic-onset juvenile idiopathic arthritis or adult onset Still disease: preliminary experience in France","volume":"67","author":"Lequerre","year":"2008","journal-title":"Ann Rheum Dis"},{"key":"R32-17-20210128","first-page":"168","article-title":"Efficacy and safety of tocilizumab, an anti-IL-6 receptor monoclonal antibody, in subjects with polyarticular or oligoarticular onset juvenile idiopathic arthritis [abstract]","volume":"54","author":"Imagawa","year":"2006","journal-title":"Arthritis Rheum"},{"key":"R33-17-20210128","doi-asserted-by":"crossref","first-page":"2627","DOI":"10.1182\/blood-2004-12-4602","article-title":"Humanized antiinterleukin-6 receptor antibody treatment of multicentric Castleman disease","volume":"106","author":"Nishimoto","year":"2005","journal-title":"Blood"},{"key":"R34-17-20210128","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1002\/art.23373","article-title":"Successful treatment of a patient with Takayasu arteritis using a humanized antiinterleukin-6 receptor antibody","volume":"58","author":"Nishimoto","year":"2008","journal-title":"Arthritis Rheum"},{"key":"R35-17-20210128","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1093\/rheumatology\/ken468","article-title":"Sustained response to tocilizumab, antiinterleukin-6 receptor antibody, in two patients with refractory relapsing polychondritis","volume":"48","author":"Kawai","year":"2009","journal-title":"Rheumatology (Oxf)"}],"container-title":["Current Opinion in Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/BOR.0b013e32832f1445","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,13]],"date-time":"2021-05-13T22:59:02Z","timestamp":1620946742000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00002281-200909000-00017"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,9]]},"references-count":34,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2009]]}},"URL":"https:\/\/doi.org\/10.1097\/bor.0b013e32832f1445","relation":{},"ISSN":["1040-8711"],"issn-type":[{"value":"1040-8711","type":"print"}],"subject":[],"published":{"date-parts":[[2009,9]]}}}